Capecitabine remains the adjuvant standard of care for TNBC with residual disease | Ingrid Mayer
Вставка
- Опубліковано 13 чер 2021
- Ingrid Mayer discusses findings from the ECOG-ACRIN EA1131 trial showing no benefit of postoperative platinum-based chemotherapy versus capecitabine in patients with triple-negative breast cancer who have residual disease following neoadjuvant chemotherapy (4:01).
View more on Medicine Matters oncology: bit.ly/3fMzOa9 - Наука та технологія
